ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
-10.33%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$259M
AUM Growth
+$259M
(-29%)
Cap. Flow
-$65.8M
Cap. Flow
% of AUM
-25.47%
Top 10 Holdings %
Top 10 Hldgs %
57.74%
Holding
34
New
11
Increased
3
Reduced
11
Closed
7
Top Buys
| 1 |
Molina Healthcare
MOH
|
$13M |
| 2 |
Charles River Laboratories
CRL
|
$12.6M |
| 3 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$11.6M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$10.4M |
| 5 |
Cencora
COR
|
$9.74M |
Top Sells
| 1 |
Illumina
ILMN
|
$27.4M |
| 2 |
Envista
NVST
|
$17.7M |
| 3 |
Elevance Health
ELV
|
$16.6M |
| 4 |
Repligen
RGEN
|
$13.9M |
| 5 |
Exact Sciences
EXAS
|
$12.9M |
Sector Composition
| 1 | Healthcare | 92.57% |
| 2 | Technology | 4.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Encompass Health
EHC
$12.3B
| $25.6M | 9.91% | 400,000 +3,330 | +0.8% | +$213K |
|
2
Boston Scientific
BSX
$156B
| $19.6M | 7.57% | 600,000 -139,842 | -19% | -$4.56M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.8M | 5.73% | 500,000 +11,702 | +2% | +$347K |
|
|
NVRO
4
DELISTED
NEVRO CORP.
NVRO
| $14M | 5.41% | 140,000 +50,667 | +57% | +$5.07M |
|
5
Bristol-Myers Squibb
BMY
$96B
| $13.9M | 5.39% | 250,000 -50,000 | -17% | -$2.79M |
|
|
6
Molina Healthcare
MOH
$9.8B
| $13M | 5.03% | +93,097 | New | +$13M |
|
|
7
Charles River Laboratories
CRL
$8.04B
| $12.6M | 4.88% | +100,000 | New | +$12.6M |
|
8
Humana
HUM
$36.5B
| $12.6M | 4.86% | 40,000 -19,997 | -33% | -$6.28M |
|
|
CHNG
9
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $11.6M | 4.49% | +1,161,713 | New | +$11.6M |
|
10
Twist Bioscience
TWST
$1.63B
| $11.5M | 4.46% | 377,040 -106,104 | -22% | -$3.24M |
|
|
CTLT
11
DELISTED
CATALENT, INC.
CTLT
| $10.4M | 4.02% | +200,000 | New | +$10.4M |
|
|
12
Cencora
COR
$56.5B
| $9.74M | 3.77% | +110,000 | New | +$9.74M |
|
13
Teva Pharmaceuticals
TEVA
$21.1B
| $8.98M | 3.47% | +1,000,000 | New | +$8.98M |
|
14
McKesson
MCK
$85.4B
| $8.79M | 3.4% | 65,000 -35,000 | -35% | -$4.73M |
|
15
Baxter International
BAX
$12.7B
| $8.12M | 3.14% | +100,000 | New | +$8.12M |
|
|
INOV
16
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $7.61M | 2.94% | 456,651 -177,057 | -28% | -$2.95M |
|
17
HCA Healthcare
HCA
$94.5B
| $7.19M | 2.78% | 80,000 -75,000 | -48% | -$6.74M |
|
18
Zimmer Biomet
ZBH
$21B
| $7.08M | 2.74% | 70,000 -125,664 | -64% | -$12.7M |
|
19
Intuitive Surgical
ISRG
$170B
| $6.93M | 2.68% | 14,000 -3,333 | -19% | -$1.65M |
|
20
Schrodinger
SDGR
$1.44B
| $6.47M | 2.5% | +150,000 | New | +$6.47M |
|
21
Heron Therapeutics
HRTX
$207M
| $5.87M | 2.27% | +500,000 | New | +$5.87M |
|
22
DexCom
DXCM
$29.5B
| $5.39M | 2.08% | 20,000 -25,734 | -56% | -$6.93M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $5.08M | 1.97% | +200,000 | New | +$5.08M |
|
24
Brookdale Senior Living
BKD
$1.83B
| $4.68M | 1.81% | +1,500,000 | New | +$4.68M |
|
25
Adaptive Biotechnologies
ADPT
$2.01B
| $4.17M | 1.61% | 150,000 | – | – |
|